Mammotome Enhances Access to Innovative HydroMARK™ Plus Breast Biopsy Markers in Europe

Mammotome Expands Access to Innovative Breast Biopsy Site Marker

Mammotome, a prominent company under the Danaher group, has made a significant advancement in breast care by obtaining the CE mark for its HydroMARK™ Plus breast biopsy site marker. This milestone is particularly important as it broadens the availability of innovative marking technology throughout Europe, addressing the needs of patients undergoing diagnosis and treatment for breast cancer.

Enhanced Technology for Improved Outcomes

The HydroMARK™ Plus markers are designed to enhance adherence to tissues and minimize marker movement during surgical excisions. These markers utilize an exclusive hydrogel technology combined with innovative structures known as Wings that Cling™. The hydrogel support hydrates within a mere 24 hours, ensuring ultrasound visibility for up to 12 months, even for patients undergoing neoadjuvant chemotherapy, mitigating the risks associated with surgical displacement.

Doctors can rely on the HydroMARK™ Plus markers, as they are designed to be visible under ultrasound, mammography, and MRI, making them suitable for placement in breast tissue and lymph nodes. Olaf Andrich, the General Manager for EMEA at Mammotome, emphasized that reducing the risk of displacement during surgery is paramount for breast care specialists who are guiding their patients through treatment. He stated, “The HydroMARK™ Plus markers have been designed with stability and visibility in mind, providing clinicians confidence that the marker remains with the target tissue during surgical intervention.”

Comprehensive Range of Products

Mammotome offers an extensive selection of breast biopsy site markers, these latest HydroMARK™ Plus markers being part of that range. This comprehensive product line empowers physicians to select the appropriate markers for various clinical requirements. Having already received FDA clearance and Health Canada's approval, as well as the CE mark, the HydroMARK™ Plus strengthens Mammotome's commitment to expanding access to cutting-edge breast care technologies globally.

As the rollout of the HydroMARK™ Plus markers commences in Europe, Mammotome anticipates a gradual introduction across select markets. For medical professionals seeking advanced solutions for breast biopsy procedures, these markers represent a significant enhancement in precision and reliability during surgeries.

About Mammotome

Mammotome stands as an essential partner for physicians, clinicians, and patients alike, thanks to its expertise and dedication to breast care. The company aims to revolutionize breast treatment methods while showing compassion for those they serve. Their innovative spirit matches their commitment to providing better outcomes through a complete product range, alongside educational resources that assist physicians and support patients through their experiences. Based in Cincinnati, Ohio, Mammotome has been part of the Danaher Corporation since 2014 and offers its products in over 65 countries worldwide.

About Danaher Corporation

Danaher Corporation is a global leader in life sciences and diagnostics, aiming to enhance human health through advanced scientific and technological solutions. Through their interconnected ecosystem of industry-leading companies, Danaher collaborates with clients to tackle the most intricate scientific and clinical challenges, accelerating the path to crucial innovations for patients in need. Their ongoing commitment to operational excellence and continuous improvement is a testament to their mission of enhancing the quality of life globally while forging a healthier and more sustainable future.